November 08, 2016 / 7:30 am, CET
Anke Linnartz has joined MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) as Vice President and Head of Corporate Communications and Investor Relations effective November 1, 2016. Reporting to Chief Financial Officer Jens Holstein, she succeeds Dr. Claudia Gutjahr-Löser, who after serving MorphoSys for nearly 15 years will leave the Company at her own request at the end of November 2016 in order to take up new challenges.
Anke Linnartz joins MorphoSys from Gerresheimer AG, a leading global partner to the pharma and healthcare industries listed in the German mid cap selection index M-Dax, where she headed the Investor Relations und Creditor Relations department from 2008 to 2016. Prior to that, she was in charge of the capital markets communications at German M-DAX company Demag Cranes AG. Before that, she headed the capital markets communications of GEA Group AG, managing the communications of a transformative group restructuring process. From 1998 to 2004, she worked in leading positions for German business intelligence company MIS AG. Anke Linnartz was member of the Board of Directors of the German Investor Relations Association (DIRK) for nine years.
"We wish to thank Claudia Gutjahr-Löser for so many years of her outstanding commitment to MorphoSys and regret her departure. She has been instrumental in raising the profile of MorphoSys to today's high level and contributed considerably to the corporate success in the past 15 years", commented Jens Holstein, Chief Financial Officer of MorphoSys AG. "At the same time, we are extremely happy that we have gained with Anke Linnartz a highly experienced and competent capital markets expert as successor for this important corporate function in our company. We wish her a good start and every success in her new role at MorphoSys".
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Head of Corporate Communications & IR
Associate Director Corporate Communications & IR
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404